Clinical Trials of COVID-19 in China

Abstract

This article hopes to summarize the fundamental attributes of \nenlisted preliminaries of 2019 novel (COVID-19), to the \nextent their spatial and transitory scatterings, kinds of \nplan and mediations, and patient characteristics among \nothers. A sweeping inquiry of the enlisted COVID-19 \npreliminaries has been performed on stages including \nClinicalTrials.gov, WHO International Clinical Trials Registry \nPlatform (WHO ICTRP), Chinese Clinical Trials Registry \n(CHiCTR), Australian Clinical Trials Registry, Britain s \nNational Research Register (BNRR), Current Control Trials \n(CCT), and Glaxo Smith Kline Register. Starters enrolled at \nthe underlying two months of the COVID-19 erupt are \nconsolidated, without language restrictions. For every \nassessment, the enlistment information, study plan, and chief \ninformation are assembled and summarized.